ESTRO 37 Abstract book

Debate This house believes that 5x5 Gy offers more opportunities for tailor made treatment than conventional chemoradiotherapy in rectal cancer patients. ..................................... (Abs. 343-346) Symposium Prostate brachytherapy: LDR seeds versus HDR monotherapy........................................ (Abs. 347-350) Debate The technological advancement in radiotherapy in the last decade was driven by economics, not clinical needs................................................................................ (Abs. 351-352) Symposium Applications of machine learning in radiation oncology.................................................. (Abs. 353-355) Advanced image acquisition for planning..................................................................... (Abs. 356-358) Medical writing and publishing................................................................................... (Abs. 359-362) Poster Viewing Poster viewing 7: RTT. ............................................................................................. (Abs. 363-371) Symposium Oligometastatic disease............................................................................................ (Abs. 372-375) Proffered Papers RB 4: Targeting tumour biology................................................................................. (Abs. 376-382) CL 7: Hematological Malignancies/Sarcoma/Palliation. .................................................. (Abs. 383-389) CL 8: Gynaecology................................................................................................... (Abs. 390-396) BT 4 - Brachytherapy rectum and breast..................................................................... (Abs. 397-403) PH 7: Dose measurement and dose calculations........................................................... (Abs. 404-410) PH 8: 4D imaging and motion management................................................................. (Abs. 411-417) RTT 4: Image acquisition and registration................................................................... (Abs. 418-424) Poster Viewing Poster viewing 8: Head and neck............................................................................... (Abs. 425-433) Award Lecture Iridium Award Lecture.................................................................................................... (Abs. 434) Teaching Lecture A primer on Value Based Health Care. .............................................................................. (Abs. 435) The systematic use of patient reported outcome measures (PROM) for the improvement of radiotherapy................................................................................ (Abs. 436) DNA Repair: from mechanisms to clinical implication. ......................................................... (Abs. 437) Is stereotactic body radiotherapy an alternative to surgery in operable patients with stage I NSCLC?. ..................................................................................................... (Abs. 438) Testis........................................................................................................................... (Abs. 439) The state of affairs with ion RBE models. .......................................................................... (Abs. 440) Prospective risk analysis: basics and applications to treatment QA........................................ (Abs. 441) SBRT/SRS: Indications, side effects, outcomes. ................................................................. (Abs. 442) Symposium Value-based radiation oncology. ................................................................................ (Abs. 443-445) Radiomics – Technical and clinical challenges and opportunities...................................... (Abs. 446-448) Genomic Instability and DNA repair in cancer. ............................................................. (Abs. 449-451) The evolving role of radiotherapy in the management of lung cancer............................... (Abs. 452-455) Debate This house believes that active surveillance is a good option for the management of low risk prostate cancer patients............................................................................ (Abs. 456-457) Symposium Advanced dosimetry methods for dose-volume effects modelling.................................... (Abs. 458-461) Dose mapping and dose accumulation........................................................................ (Abs. 462-464) Stereotactic RT and radiosurgery............................................................................... (Abs. 465-467) Poster Viewing Poster viewing 9: SBRT and arthritis........................................................................... (Abs. 468-476) Symposium Enhancing radiation oncology outcomes through patient involvement.............................. (Abs. 477-480) Radiogenomics........................................................................................................ (Abs. 481-484)

MONDAY 23 APRIL 2018